Cargando…

The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy

Mesenchymal stem cells (MSCs) are ideal for cell-based therapy in various inflammatory diseases because of their immunosuppressive and tissue repair properties. Moreover, their immunosuppressive properties and low immunogenicity contribute to a reduced or weakened immune response elicited by the imp...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jun, Huang, Xiaowen, Wang, Haijun, Liu, Xiaoyan, Zhang, Tao, Wang, Yunchuan, Hu, Dahai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665863/
https://www.ncbi.nlm.nih.gov/pubmed/26620426
http://dx.doi.org/10.1186/s13287-015-0240-9
_version_ 1782403627401347072
author Zhang, Jun
Huang, Xiaowen
Wang, Haijun
Liu, Xiaoyan
Zhang, Tao
Wang, Yunchuan
Hu, Dahai
author_facet Zhang, Jun
Huang, Xiaowen
Wang, Haijun
Liu, Xiaoyan
Zhang, Tao
Wang, Yunchuan
Hu, Dahai
author_sort Zhang, Jun
collection PubMed
description Mesenchymal stem cells (MSCs) are ideal for cell-based therapy in various inflammatory diseases because of their immunosuppressive and tissue repair properties. Moreover, their immunosuppressive properties and low immunogenicity contribute to a reduced or weakened immune response elicited by the implantation of allogeneic MSCs compared with other cell types. Therefore, implantation of allogeneic MSCs may be a promising cell-based therapy. In this review, we first summarize the unique advantages of allogeneic MSCs for therapeutic applications. Second, we critically analyze the factors influencing their therapeutic effects, including administration routes, detection time-points, disease models, differentiation of MSCs in vivo, and timing and dosage of MSC administration. Finally, current approaches to allogeneic MSC application are discussed. In conclusion, allogeneic MSCs are a promising option because of their low immunogenicity and immunosuppressive and tissue repair capabilities. Further investigations are needed to enhance the consistency and efficacy of MSCs when used as a cell-based therapy in inflammatory diseases as well as for tissue repair.
format Online
Article
Text
id pubmed-4665863
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46658632015-12-02 The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy Zhang, Jun Huang, Xiaowen Wang, Haijun Liu, Xiaoyan Zhang, Tao Wang, Yunchuan Hu, Dahai Stem Cell Res Ther Review Mesenchymal stem cells (MSCs) are ideal for cell-based therapy in various inflammatory diseases because of their immunosuppressive and tissue repair properties. Moreover, their immunosuppressive properties and low immunogenicity contribute to a reduced or weakened immune response elicited by the implantation of allogeneic MSCs compared with other cell types. Therefore, implantation of allogeneic MSCs may be a promising cell-based therapy. In this review, we first summarize the unique advantages of allogeneic MSCs for therapeutic applications. Second, we critically analyze the factors influencing their therapeutic effects, including administration routes, detection time-points, disease models, differentiation of MSCs in vivo, and timing and dosage of MSC administration. Finally, current approaches to allogeneic MSC application are discussed. In conclusion, allogeneic MSCs are a promising option because of their low immunogenicity and immunosuppressive and tissue repair capabilities. Further investigations are needed to enhance the consistency and efficacy of MSCs when used as a cell-based therapy in inflammatory diseases as well as for tissue repair. BioMed Central 2015-12-01 /pmc/articles/PMC4665863/ /pubmed/26620426 http://dx.doi.org/10.1186/s13287-015-0240-9 Text en © Zhang et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Zhang, Jun
Huang, Xiaowen
Wang, Haijun
Liu, Xiaoyan
Zhang, Tao
Wang, Yunchuan
Hu, Dahai
The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy
title The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy
title_full The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy
title_fullStr The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy
title_full_unstemmed The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy
title_short The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy
title_sort challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665863/
https://www.ncbi.nlm.nih.gov/pubmed/26620426
http://dx.doi.org/10.1186/s13287-015-0240-9
work_keys_str_mv AT zhangjun thechallengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT huangxiaowen thechallengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT wanghaijun thechallengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT liuxiaoyan thechallengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT zhangtao thechallengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT wangyunchuan thechallengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT hudahai thechallengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT zhangjun challengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT huangxiaowen challengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT wanghaijun challengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT liuxiaoyan challengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT zhangtao challengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT wangyunchuan challengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy
AT hudahai challengesandpromisesofallogeneicmesenchymalstemcellsforuseasacellbasedtherapy